Health Condition 1: null- Psoriasis
Conditions
Interventions
Intervention1: Vajraka Ghrita,Arogyavardhini vati,Dineshavalyadi taila: Vajraka Ghrita 6gm twice daily with luke warm water - 12 weeks
2.Arogyavardhini vati 250mg twice daily - 12 weeks
3.Dineshavalya
Sponsors
Central Council for Research in Ayurvedic Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1.Known cases of psoriasis, without psoriatic arthropathy, Exhibiting psoriatic triad â?? I.Bright pink or red lesions with pronounced edges, covered with silvery white scales, the scales can be easily separated from the lesion II.Under the scales there appears a pinkish moist tender skin III.With the scarping of the moist skin there appear tiny blood droplets (Auspitzâ??s sign) 2.Patients suffering from mild to moderate psoriasis with less than 50 % of the body surface involvement 3.Patients having less than 10 years duration 4.Positive histopathological finding.(Skin-biopsy - optional)
Exclusion criteria
Exclusion criteria: 1.Age below 18 years and above 60 years 2.Patients with other forms of Psoriasis like Guttate/ Pustular/ Erythrodermic/ inverse. 3.Patients suffering from severe psoriasis with more than 50% of the body surface involvement 4.Patients having chronic disease i.e. more than10 years duration 5.Patients who cannot report in person every 2 weeks in the OPD 6.Patients with Psoriatic arthropathy 7.Patients with poorly controlled Hypertension ( >160/100 mmHg) 8.Patients with poorly controlled Diabetes Mellitus having Hb A1C of > 7.5% 9.Patients on medication with corticosteroids, phototherapy, biologics, antidepressants any other drugs that may have an influence on the outcome of the study. 10.Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months. 11.Symptomatic patient with clinical evidence of Heart failure. 12.Known HIV positive cases 13.Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) > 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine >1.2mg/dL), Severe Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease [COPD]), or any other condition that may jeopardize the study. 14.Alcoholics and/or drug abusers 15.H/o hypersensitivity to any of the trial drugs or their ingredients 16. Pregnant/lactating woman. 17.Patients who have completed participation in any other clinical trial during the past six months. 18.Any other condition which the Investigator thinks may jeopardize the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| â?¢Relief in Signs & Symptoms (Change in baseline in plaque psoriasis) of the disease by Reduction in Psoriasis Area and Severity Index (PASI) Score, PASI 50 (50% improvement in PASI score)Timepoint: 12 Weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| â?¢Relief in Signs & Symptoms (Change in baseline in plaque psoriasis) of PASI 25. â?¢Improvement in Dermatology Life Quality Index (DLQI) Questionnaire. â?¢Any adverse drug reaction or event noted during the trialTimepoint: 12 Weeks | — |
Countries
India
Contacts
Public ContactDr R Kumara Swamy
Centra Council for Research in Ayurvedic Sciences
Outcome results
None listed